The drastic reduction of carbon emission to combat global climate change cannot be realized without a significant contribution from the electricity sector. Renewable energy resources must take a ...bigger share in the generation mix, effective demand response must be widely implemented, and high-capacity energy storage systems must be developed. A smart grid is necessary to manage and control the increasingly complex future grid. Certain smart grid elements-renewables, storage, microgrid, consumer choice, and smart appliances-increase uncertainty in both supply and demand of electric power. Other smart gird elements-sensors, smart meters, demand response, and communications-provide more accurate information about the power system and more refined means of control. Simply building hardware for renewable generators and the smart grid, but still using the same operating paradigm of the grid, will not realize the full potential for overall system efficiency and carbon reduction. In this paper, a new operating paradigm, called risk-limiting dispatch, is proposed. It treats generation as a heterogeneous commodity of intermittent or stochastic power and uses information and control to design hedging techniques to manage the risk of uncertainty.
The ARGO-YBJ air shower detector monitored the Crab Nebula gamma-ray emission from 2007 November to 2013 February. The integrated signal, consisting of ~3.3 x 10 super(5) events, reached the ...statistical significance of 21.1 standard deviations. The obtained energy spectrum in the energy range 0.3-20 TeV can be described by a power law function dN/dE = I sub(0) (E/2 TeV) super(-alpha), with a flux normalization I sub(0) = (5.2 + or - 0.2) x 10 super(-12) photons cm super(-2) s super(-1) TeV super(-1) and alpha = 2.63 + or - 0.05, corresponding to an integrated flux above 1 TeV of 1.97 x 10 super(-11) photons cm super(-2) s super(-1). The systematic error is estimated to be less than 30% for the flux normalization and 0.06 for the spectral index. Assuming a power law spectrum with an exponential cutoff dN/dE = I sub(0) (E/2 TeV) super(-alpha) exp (-E/E sub(cut)), the lower limit of the cutoff energy E sub(cut) is 12 TeV, at 90% confidence level. Our extended data set allows the study of the TeV emission over long timescales. Over five years, the light curve of the Crab Nebula in 200-day bins is compatible with a steady emission with a probability of 7.3 x 10 super(-2). A correlated analysis with Fermi-LAT data over ~4.5 yr using the light curves of the two experiments gives a Pearson correlation coefficient r = 0.56 + or - 0.22. Concerning flux variations on timescales of days, a "blind" search for flares with a duration of 1-15 days gives no excess with a significance higher than four standard deviations. The average rate measured by ARGO-YBJ during the three most powerful flares detected by Fermi-LAT is 205 + or - 91 photons day super(-1), consistent with the average value of 137 + or - 10 day super(-1).
Perovskite material with a bandgap of 1.7–1.8 eV is highly desirable for the top cell in a tandem configuration with a lower bandgap bottom cell, such as a silicon cell. This can be achieved by ...alloying iodide and bromide anions, but light-induced phase-segregation phenomena are often observed in perovskite films of this kind, with implications for solar cell efficiency. Here, we investigate light-induced phase segregation inside quadruple-cation perovskite material in a complete cell structure and find that the magnitude of this phenomenon is dependent on the operating condition of the solar cell. Under short-circuit and even maximum power point conditions, phase segregation is found to be negligible compared to the magnitude of segregation under open-circuit conditions. In accordance with the finding, perovskite cells based on quadruple-cation perovskite with 1.73 eV bandgap retain 94% of the original efficiency after 12 h operation at the maximum power point, while the cell only retains 82% of the original efficiency after 12 h operation at the open-circuit condition. This result highlights the need to have standard methods including light/dark and bias condition for testing the stability of perovskite solar cells. Additionally, phase segregation is observed when the cell was forward biased at 1.2 V in the dark, which indicates that photoexcitation is not required to induce phase segregation.
The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody ...response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
Display omitted
•Cross-reactive antigen binding is common between SARS-CoV and SARS-CoV-2•Cross-reactive antibody responses target both RBD and non-RBD regions•Cross-neutralization of live viruses may be rare between SARS-CoV and SARS-CoV-2
Lv et al. examine the antibody responses from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. The results show that cross-reactive binding to the spike protein is common, whereas cross-neutralization of the live viruses may be rare.
The information on the projected climate changes over China is of great importance for preparing the nation’s societal adaptiveness to the future natural ecosystem. This study reports the surface ...mean temperature changes during 2014–2100 over China and its four sub-regions (Northern China, Northwestern China, Southern China, and the Tibetan Plateau) by analyzing 20 models from the Coupled Model Intercomparison Project Phase 6 (CMIP6) under three Shared Socio-economic Pathway (SSP) scenarios: SSP126, SSP245 and SSP585. The multi-model ensemble mean (MMEM) of 20 CMIP6 models has cold biases over China during 1979–2014, with improved performance compared with the CMIP5 models. In contrast, the CMIP6 models simulate well in the spatial climatology with lower warming rates over China. Relative to 1986–2005, the regionally averaged surface mean temperatures from the MMEM over China under SSP126, SSP245, SSP585 scenarios are projected to increase by 1.31 °C, 1.32 °C, 1.45 °C in the near-term (2021–2040), 1.75 °C, 2.06 °C, 2.66 °C in the mid-term (2041–2060), and 1.08 °C, 2.97 °C, 5.62 °C in the long-term (2081–2100), respectively. The CMIP6 models simulate accelerated warming occurs over the Northwestern China and the Tibetan Plateau, suggesting that the arid and semi-arid regions are particularly sensitive to future climate warming. We quantify uncertainty for future projections of temperature changes over China, and the main sources of uncertainty are model and scenario uncertainty particularly for the regions with the largest cold bias. This suggests that the observational constraints on these regions will lead to significant improvements for climatic projections over China.
This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients with platinum-sensitive recurrent ovarian cancer.
In this phase III, ...double-blind, placebo-controlled study conducted at 30 centers in China, adults with platinum-sensitive recurrent ovarian cancer who had responded to their most recent platinum-containing chemotherapy were randomized 2 : 1 to receive oral niraparib (300 mg/day) or matched placebo until disease progression or unacceptable toxicity (NCT03705156). Following a protocol amendment, patients with a bodyweight <77 kg or a platelet count <150 × 103/μl received 200 mg/day, and all other patients 300 mg/day, as an individualized starting dose (ISD). Randomization was carried out by an interactive web response system and stratified by BRCA mutation, time to recurrence following penultimate chemotherapy, and response to most recent chemotherapy. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review.
Between 26 September 2017 and 2 February 2019, 265 patients were randomized to receive niraparib (n = 177) or placebo (n = 88); 249 patients received an ISD (300 mg, n = 14; 200 mg, n = 235) as per protocol. In the intention-to-treat population, median PFS was significantly longer for patients receiving niraparib versus placebo: 18.3 95% confidence interval (CI), 10.9-not evaluable versus 5.4 (95% CI, 3.7-5.7) months hazard ratio (HR) = 0.32; 95% CI, 0.23-0.45; P < 0.0001, and a similar PFS benefit was observed in patients receiving an ISD, regardless of BRCA mutation status. Grade ≥3 treatment-emergent adverse events occurred in 50.8% and 19.3% of patients who received niraparib and placebo, respectively; the most common events were neutrophil count decreased (20.3% versus 8.0%) and anemia (14.7% versus 2.3%).
Niraparib maintenance treatment reduced the risk of disease progression or death by 68% and prolonged PFS compared to placebo in patients with platinum-sensitive recurrent ovarian cancer. Individualized niraparib dosing is effective and safe and should be considered standard practice in this setting.
•Chinese patients with platinum-sensitive recurrent ovarian cancer received maintenance niraparib (n = 177) or placebo (n = 88).•Median PFS was longer for niraparib versus placebo: 18.3 versus 5.4 months (HR = 0.32; 95% CI, 0.23-0.45; P < 0.0001).•Niraparib had a similar PFS benefit for 249 patients receiving individualized dosing based on bodyweight and platelet count.•Grade ≥3 treatment-emergent adverse events occurred in 50.8% and 19.3% of patients who received niraparib and placebo, respectively.•In the niraparib group, Grade ≥3 platelet count decreased/thrombocytopenia occurred in 11.3% of patients.
Adenosquamous carcinoma (ASC) of the lung is a heterogeneous disease that is composed of both adenocarcinoma components (ACC) and squamous cell carcinoma components (SCCC). Their genomic profile, ...genetic origin, and clinical management remain controversial.
Resected ASC and metastatic tumor in regional lymph nodes (LNs) were collected. The ACC and SCCC were separated by microdissection of primary tumor. The 1021 cancer-related genes were evaluated by next-generation sequencing independently in ACC and SCCC and LNs. Shared and private alterations in the two components were investigated. In addition, genomic profiles of independent cohorts of adenocarcinomas and squamous cell carcinomas were examined for comparison. We have also carried out a retrospective study of ASCs with known EGFR mutation status from 11 hospitals in China for their clinical outcomes.
The most frequent alterations in 28 surgically resected ASCs include EGFR (79%), TP53 (68%), MAP3K1 (14%) mutations, EGFR amplifications (32%), and MDM2 amplifications (18%). Twenty-seven patients (96%) had shared variations between ACC and SCCC, and pure SCCC metastases were not found in metastatic LNs among these patients. Only one patient with geographically separated ACC and SCCC had no shared mutations. Inter-component heterogeneity was a common genetic event of ACC and SCCC. The genomic profile of ASC was similar to that of 170 adenocarcinomas, but different from that of 62 squamous cell carcinomas. The incidence of EGFR mutations in the retrospective analysis of 517 ASCs was 51.8%. Among the 129 EGFR-positive patients who received EGFR-TKIs, the objective response rate was 56.6% and the median progression-free survival was 10.1 months (95% confidence interval: 9.0–11.2).
The ACC and SCCC share a monoclonal origin, a majority with genetically inter-component heterogeneity. ASC may represent a subtype of adenocarcinoma with EGFR mutation being the most common genomic anomaly and sharing similar efficacy to EGFR TKI.
•The adenocarcinoma component and squamous cell carcinoma component of adenosquamous carcinoma share a common clonal origin.•High incidence of trunk EGFR and TP53 mutation were noted in adenosqumous cell carcinoma, while the overall genomic profile of adenosqumous cell carcinoma is more similar to adenocarcinoma than squmous cell carcinoma.•EGFR-TKIs should be the standard first-line therapy for advanced stage adenosquamous carcinoma with EGFR mutation.
The diagnosis of chronic pancreatitis remains challenging in early stages of the disease. This report defines the diagnostic criteria useful in the assessment of patients with suspected and ...established chronic pancreatitis. All current diagnostic procedures are reviewed, and evidence-based statements are provided about their utility and limitations. Diagnostic criteria for chronic pancreatitis are classified as definitive, probable, or insufficient evidence. A diagnostic (STEP-wise; survey, tomography, endoscopy, and pancreas function testing) algorithm is proposed that proceeds from a noninvasive to a more invasive approach. This algorithm maximizes specificity (low false-positive rate) in subjects with chronic abdominal pain and equivocal imaging changes. Furthermore, a nomenclature is suggested to further characterize patients with established chronic pancreatitis based on TIGAR-O (toxic, idiopathic, genetic, autoimmune, recurrent, and obstructive) etiology, gland morphology (Cambridge criteria), and physiologic state (exocrine, endocrine function) for uniformity across future multicenter research collaborations. This guideline will serve as a baseline manuscript that will be modified as new evidence becomes available and our knowledge of chronic pancreatitis improves.
Co‐nanostructuring of PbTe with two kinds of metallic nanoparticles (Pb and Sb) can significantly increase its power factor at high temperatures (up to 87 % at 700 K; see picture, ZT=figure of ...merit). The electrical conductivity is dramatically increased at high temperatures without degrading the thermopower. This emergent synergy results only when both Pb and Sb nanocrystals are present.
PDF
